Navigation Links
ULURU Inc. to Present at the 8th World Biomaterials Congress
Date:5/28/2008

- Invited Oral Presentation by Dr. John St. John - - Three Poster Presentations on the Hydrogel Nanoparticle Technology -

ADDISON, Texas, May 28 /PRNewswire-FirstCall/ -- ULURU Inc. (Amex: ULU) today announced that at the upcoming 8th World Biomaterials Congress, to be held in Amsterdam from May 28th to June 1, 2008, Dr. John St. John, ULURU's Vice President of Material Science, will give an invited oral presentation along with the presentation of three posters.

The title of the invited oral presentation is "Strategies for Tissue Regeneration in Wound Healing with Controlled Release of Actives from Hydrogel Nanoparticle Wound Dressings". This presentation will be made in the session "Tissue Repair and Regeneration" to be conducted on June 1, 2008.

A poster titled "Control of Vascular Proliferation and Healing in Acute Wounds with Controlled Release of VEGF from Hydrogel Nanoparticle Dressings" will be presented in a session on May 31, 2008. Additionally, two posters will be presented at the "Biomaterials for Plastic Surgery -- Poster Session" on May 31, 2008. The titles of these posters are "Formulation and Preclinical Evaluation of Hydrogel Nanoparticle-Hyaluronic Acid Dermal Fillers" and "Hydrogel Nanoparticle Gels as Breast Implant Filler Materials."

Commenting on the upcoming presentation Dr. John St. John stated "I am very pleased to be an invited speaker at this prestigious Biomaterials Congress. This Congress gives ULURU the opportunity to showcase our hydrogel nanoparticle aggregate technology along with a portion of the extensive body of work that we have accumulated supporting our product developments. Additionally, this is an ideal forum to present a representative part of the extensive data that we have generated on the controlled release of active agents to improve wound healing."

Utilizing the experience we are gaining in the United States, we are planning to roll out the launch of Altrazeal(TM), ULURU's first wound dressing utilizing our nanoparticle aggregate technology, extensively throughout the world in the upcoming 12 months. Activities are ongoing to secure a CE mark designation by year-end 2008 which would enable Altrazeal(TM) to be marketed throughout Europe and other international markets. The initial wound dressing containing an active agent, silver, an anti microbial and anti bacterial agent, has recently completed the necessary GLP toxicology studies and we expect to file for 510k approval with the FDA in the second half of 2008.

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management, oral care and plastic surgery products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its Hydrogel Nanoparticle Aggregate technology and innovative transmucosal delivery system. For further information about ULURU Inc., please visit our website at http://www.uluruinc.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to our expectation of filing a 510k in the second half of 2008, the expectation of rolling out the launch of Altrazeal(TM) extensively throughout the world in the upcoming 12 months and the expectation of securing of a CE Mark designation by year-end 2008. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007, Quarterly Report on Form 10-Q for the quarter ended March 31, 2008 and other reports filed by us with the Securities and Exchange Commission.

Contact: Company

Kerry P. Gray

President & CEO

Terry K. Wallberg

Vice President & CFO

(214) 905-5145


'/>"/>
SOURCE ULURU Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CV Therapeutics Announces Presentations at the American Diabetes Association 68th Scientific Sessions
2. CryoLife to Present at FBR Capital Markets Annual Spring Investor Conference
3. Inverness Medical Innovations to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 28, 2008
4. Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
5. Amylin Pharmaceuticals to Present at FBR Capital Markets Investor Conference
6. SuperGen to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008
7. AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting
8. West Pharmaceutical Services to Present at the 2008 UBS Global Specialty & Generic Pharmaceuticals Conference
9. Martek to Present at Upcoming UBS Conference
10. eResearchTechnology to Present at the FBR 12th Annual Spring Investor Conference on May 28th 2008
11. Presentation of Landmark Clinical Trial Evaluating Endoscopic Treatment for Pre-cancerous Condition of Esophagus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)...  In five studies being presented today during the ... Exposition in San Diego , researchers ... delivery of life-saving treatments to patients with a variety ... carry therapies directly to the sites in the body ... substantial advantage over traditional, systemic methods. The studies highlight ...
(Date:12/2/2016)... HARBOR, N.Y. , Dec. 2, 2016 More ... Laboratory,s (CSHL) 11th Double Helix Medals dinner ( DHMD ). The gala ... in New York City and honored ... for their contributions, respectively, to health and medicine and the ... Muhammad Ali in 2006, the event has raised $40 ...
(Date:12/2/2016)... , Dec. 2, 2016 CytRx Corporation ... development company specializing in oncology, today announced the appointment ... sarcoma surgeon, industry consultant, and private healthcare investor, to ... a healthcare leader with clinical and strategic experience at ... CytRx,s Chairman and CEO. "As one of the world,s ...
(Date:12/2/2016)... ... December 01, 2016 , ... ... DNA microarray comparative genomic hybridization (array CGH) for HER2 genomic subtyping in ... molecular test results from tumors with previously documented positive, negative, and equivocal ...
Breaking Biology Technology:
(Date:6/21/2016)... 21, 2016 NuData Security announced today that ... of principal product architect and that Jon ... customer development. Both will report directly to ... moves reflect NuData,s strategic growth in its product ... customer demand and customer focus values. ...
(Date:6/16/2016)... FRANCISCO , June 16, 2016 ... size is expected to reach USD 1.83 ... by Grand View Research, Inc. Technological proliferation and ... banking applications are expected to drive the market ... ) , The development of advanced ...
(Date:6/9/2016)... control systems is proud to announce the introduction of fingerprint attendance control software, allowing ... are actually signing in, and to even control the opening of doors. ... ... ... Photo - http://photos.prnewswire.com/prnh/20160609/377487 ...
Breaking Biology News(10 mins):